![]() ![]() Prior to Mirati, Ben was Senior Vice President, Chief Commercial Officer at Halozyme Therapeutics, where he was responsible for the global commercial strategy for the company’s oncology portfolio. Ben has a long track record of leading commercial teams, including global product launches for innovative oncology treatments. Ben is responsible for building and leading commercial and medical affairs functions and capabilities as Mirati prepares for commercial readiness. in biology from Northern Illinois University.īen joined Mirati in 2020 as Chief Commercial Officer, bringing with him almost 20 years of industry experience. ![]() at North Carolina State University and his B.S. In addition, he also participates on the editorial boards for Cancer Research and Molecular Cancer Therapeutics and is a member of the Scientific Advisory panel at Bridge Bio/QED. Jamie currently serves as a member of the board of directors at Boundless Bio and has authored or co-authored over 140 peer-reviewed research articles in scientific journals including Science, Nature, Cancer Cell, Cancer Discovery, New England Journal of Medicine and many others. He began his industry experience at Warner Lambert/Parke-Davis. Prior to Pfizer, Jamie held positions at SUGEN/Pharmacia as a Group Leader on the Preclinical Research and Exploratory Development team. He joined Pfizer in 2003, and his responsibilities included leading oncology nonclinical research and translational sciences for programs including Sutent* and Xalkori.* Prior to Mirati, Jamie was the head of Oncology Precision Medicine and a member of the executive leadership team in the Oncology Research Unit at Pfizer. At Mirati, Jamie has led activities related to the discovery and advancement of the company’s clinical and preclinical programs, including adagrasib (KRAS G12C selective inhibitor), MRTX1133 (KRAS G12D selective inhibitor) and sitravatinib (spectrum-selective receptor tyrosine kinase (RTK) inhibitor). ![]() In his role, Jamie is responsible for drug discovery, translational research, drug manufacturing and companion diagnostics research. Jamie joined Mirati in 2013 as Chief Scientific Officer. * Trademarks are property of their respective owners. Additionally, he has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts and holds a number of patents and patent applications. degrees from Washington University School of Medicine and completed his post-graduate training at Stanford University. Previously, he served as a member of the board of Array Biopharma from 2014 to 2019 when it was acquired by Pfizer, Inc., Immunomedics from 2019 to 2020 when it was acquired by Gilead, and BCTG Acquisition Corp from 2020 to 2021 when it merged with Tango Therapeutics.Ĭhuck received his M.D. Chuck is also on the Scientific Advisory Board at ALX Oncology. He currently serves on the board of directors at Poseida Therapeutics, PMV Pharma, Acrivon Therapeutics, Odyssey Therapeutics and Terremoto Biosciences. He was responsible for the development of Pfizer’s oncology portfolio, including Inlyta,* Xalkori* and the approval of Sutent.* Prior to Pfizer, Chuck was at Schering-Plough where he was responsible for the Phase I-IV development of several oncology compounds, including Temodar.*Ĭhuck’s career has also included academic and hospital positions at Stanford and Emory universities. He was at Pfizer from 2003 to 2012, serving in roles of increasing responsibility, including Vice President, Head of Oncology Development and Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. Prior to joining Mirati, Chuck was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. Under his leadership, Mirati has transformed into a precision oncology company focused on advancing drug discovery and research and delivering novel therapeutics that target the genetic drivers of cancer. He was Founder, President and Head of Research and Development at Mirati from 2021 to 2023 and was President, Founder and CEO from Nov 2012 to 2021. Chuck is the Founder, President and Chief Executive Officer of Mirati Therapeutics, and has been a Board Member since Nov 2012.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |